Floquet, Anne
Institut Bergonié
3 papers on CoChatORCID 0000-0002-1078-8554
Most cited papers
- Verified
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 2,870
- Verified
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Swisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 1,196
- Verified
Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial
DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology
PARP inhibition in cancer therapyBRCA gene mutations in cancer
Cited by 511
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free